Immunovant Inc (IMVT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.07B
Last updated: Nov 17, 2026 at 11:06 AM ET
Immunovant Inc (IMVT) Stock Forecast
Analysts expect Immunovant (IMVT) to earn -$2.44 per share in the fiscal year ending Mar 31, 2027. Of 17 analysts, 13 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.12, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 76% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 11.8% |
| Buy | 11 | 64.7% |
| Hold | 4 | 23.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Mar 31, 2027
- -$2.44
- EPS consensus
- Fiscal year ending Mar 31, 2028
- -$2.62
- EPS consensus, revenue $39.64M
- Next report
- Feb 4, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Mar 31, 2027 | -$2.44 | -$2.55 to -$2.26 | 3 | N/A | N/A | 13 |
| Mar 31, 2028 | -$2.62 | -$3.20 to -$2.38 | 5 | $39.64M | N/A | 13 |
Quarterly Estimates
The EPS consensus falls from -$0.58 for the quarter ending Dec 31, 2026 to -$0.76 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.58 | -$0.71 to -$0.50 | 3 |
| Mar 31, 2027 | -$0.76 | -$0.82 to -$0.66 | 16 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 7 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Mar 31, 2027 | 0 | 3 |
| Fiscal year ending Mar 31, 2028 | 0 | 3 |
| Quarter ending Dec 31, 2026 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Mar 31, 2027 has improved from -$2.92.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Mar 31, 2027 | -$2.44 | -$2.84 | -$2.84 | -$2.84 | -$2.92 | N/A |
| Fiscal year ending Mar 31, 2028 | -$2.62 | -$2.75 | -$2.75 | -$2.75 | -$2.50 | N/A |
| Quarter ending Dec 31, 2026 | -$0.58 | -$0.67 | -$0.67 | -$0.67 | -$0.74 | N/A |
Frequently Asked Questions About IMVT
What is the IMVT stock forecast?
Consensus analyst estimates put Immunovant's EPS at -$2.44 for the fiscal year ending Mar 31, 2027. The consensus rating from 17 analysts is Buy.
How do analysts rate IMVT stock?
Of 17 analysts covering Immunovant, 2 rate it Strong Buy, 11 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IMVT next year?
For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$2.44, with estimates from -$2.55 to -$2.26 from 3 analysts. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is -$2.62, with estimates from -$3.20 to -$2.38 from 5 analysts.
What revenue do analysts expect from Immunovant next year?
For the fiscal year ending Mar 31, 2028, the consensus revenue estimate is $39.64M.
How many analysts cover IMVT?
17 analysts rate Immunovant stock, and 3 analysts estimate its EPS for the fiscal year ending Mar 31, 2027.
IMVT pages: Overview, Earnings, Forecast, Financials, Competitors